Skip to main content
. 2017 Aug 15;18:268. doi: 10.1186/s12882-017-0686-3

Fig. 2.

Fig. 2

Effect of tolvaptan 60 mg during and after NO inhibition on FENa (a) and u-ENaCγ (b) in ADPKD. Data are given as medians with 25th and 75th percentiles. General linear model (GLM) with repeated measures was performed for comparison within and between groups. Paired t-test was used for comparison between tolvaptan and placebo treatment during L-NMMA infusion period (90–150 min) and post infusion period (150–210 min)